Edgewise Therapeutics (NASDAQ: EWTX) grants director equity awards

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. director Edris Badreddin received new equity-based compensation. On June 5, 2026, he was granted stock options for 8,188 shares of common stock at an exercise price of $35.59 per share, expiring on June 5, 2036. He also received 5,619 Restricted Stock Units (RSUs). According to the terms, 100% of both the options and RSUs will vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of stockholders. These are compensation grants, not open‑market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Edris Badreddin

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	5,619	$0.00	--
Grant/Award	Stock Option (Right to Buy)	8,188	$0.00	--

Holdings After Transaction: Restricted Stock Units — 5,619 shares (Direct, null); Stock Option (Right to Buy) — 8,188 shares (Direct, null)

Footnotes (1)

1. 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Key Figures

Stock options granted: 8,188 options Option exercise price: $35.59 per share RSUs granted: 5,619 RSUs +2 more

5 metrics

Stock options granted 8,188 options Granted June 5, 2026 to director

Option exercise price $35.59 per share Stock Option (Right to Buy)

RSUs granted 5,619 RSUs Granted June 5, 2026 to director

Option expiration date June 5, 2036 Stock options awarded June 5, 2026

Vesting trigger date June 5, 2027 Earlier of this date or business day before 2027 annual meeting

Key Terms

Stock Option (Right to Buy), Restricted Stock Units, exercise price, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Restricted Stock Units financial

"security_title: Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"conversion_or_exercise_price: 35.5900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-05T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vested financial

"100% of the Restricted Stock Units ... will become vested"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/16/2026 - 06:19 PM Accepted by SEC EDGAR 06/16/2026 - 06:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edris Badreddin

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	06/05/2026		A		5,619		06/02/2027(1)	06/05/2036	Common Stock	5,619	$0.00	5,619	D
Stock Option (Right to Buy)	$35.59	06/05/2026		A		8,188		06/02/2027(2)	06/05/2036	Common Stock	8,188	$0.00	8,188	D

Explanation of Responses:

1. 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

2. 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder.

Remarks:

	/s/John R. Moore Attorney-in-Fact for Badreddin Edris	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Edgewise Therapeutics (EWTX) director Edris Badreddin receive?

Director Edris Badreddin received stock options for 8,188 shares at a $35.59 exercise price and 5,619 Restricted Stock Units. Both awards are part of his director compensation and are tied to future vesting conditions.

When do EWTX director Edris Badreddin’s new stock options and RSUs vest?

All granted options and RSUs vest 100% on the earlier of June 5, 2027 or the business day before the 2027 annual stockholder meeting. This creates a single cliff-vesting date tied to time and the next annual meeting.

Are EWTX director Edris Badreddin’s Form 4 transactions open-market buys or sales?

The Form 4 shows grant or award acquisitions, not open-market trades. Badreddin received stock options and RSUs as compensation, with no shares bought or sold on the market in these reported transactions.

What are the terms of EWTX director Edris Badreddin’s new stock options?

The options cover 8,188 shares of Edgewise Therapeutics common stock at a $35.59 exercise price and expire on June 5, 2036. They vest in full on the earlier of June 5, 2027 or the business day before the 2027 annual meeting.

How many Restricted Stock Units did EWTX grant to director Edris Badreddin?

Edgewise Therapeutics granted 5,619 Restricted Stock Units to director Edris Badreddin. These RSUs convert into common shares upon vesting, which occurs on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting.